TY - JOUR AU - Serhiyenko, V.A. AU - Azhmi, S. AU - Serhiyenko, A.A. PY - 2021/09/02 Y2 - 2024/03/29 TI - Comparison of efficiency of omega-3 polyunsaturated fatty acids, statins and their combination on lipids parameters, vascular-thrombocyte homeostasis and heart rate variability parameters in patients with type 2 diabetes mellitus and cardiovascular autono JF - INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) JA - Mìžnarodnij endokrinologìčnij žurnal VL - 13 IS - 5 SE - Original Researches DO - 10.22141/2224-0721.13.5.2017.110020 UR - https://iej.zaslavsky.com.ua/index.php/journal/article/view/398 SP - 315-323 AB - <p class="a"><strong><em>Background.</em></strong><strong> </strong>The analysis of combined omega-3 polyunsaturated fatty acids (w-3 PUFAs) and statins prescription to patients with cardiac autonomic neuropathy (CAN) and type 2 diabetes mellitus (T2DM) is of great interest. However existing data about features of their prescription are fragmentary, under discussion and thus require further investigation. Purpose of the study was to compare the influence of w-3 PUFAs, statins and their combination on lipids parameters, vascular-thrombocyte homeostasis and heart rate variability (HRV) parameters in patients with T2DM and CAN. <strong><em>Materials and methods.</em></strong><strong> </strong>The study involved 75 patients with T2DM and functional stage of CAN. The concentration of glucose, HbA<sub>1c</sub>, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), endothelin-1 (ET-1), thromboxane B<sub>2</sub> (TXB<sub>2</sub>), 6-ketoprostoglandine F<sub>1</sub><sub>a</sub> (6-ketoPGF<sub>1</sub><sub>a</sub>) in the blood were determined; atherogenic coefficient (AC) and TXB<sub>2</sub>/6-ketoPGF<sub>1</sub><sub>a</sub> were calculated. Short time HRV was analyzed using time and spectral parameters. Patients with T2DM and functional stage of CAN were divided into four groups: patients in the 1<sup>st </sup>group (n = 21) received one capsule/day of w-3 PUFAs in addition to standard treatment; patients in the 2<sup>nd </sup>group (n = 22) received simvastatin 20 mg/daily; patients of the 3<sup>rd </sup>group (n = 17) received one capsule of w-3 PUFAs and simvastatin 10 mg/daily; patients of the 4<sup>rd </sup>group (n = 22) took standard glucose lowering therapy (control group). The study lasted 3 months. <strong><em>Results.</em></strong><strong> </strong>Administration of w-3 PUFAs to patients with T2DM and CAN promoted to the statistically significant decrease in TG, AC and increase of HDL-C, but no significant changes of TC and LDL-C was found. Prescription of simvastatin was accompanied by statistically significant decrease in TC, LDL-C, AC, ТХВ<sub>2</sub>, TXB<sub>2</sub>/6-ketoPGF<sub>1</sub><sub>a</sub> and increase in HDL-C, ЕТ-1, 6-ketoPGF<sub>1</sub><sub>a</sub> levels; time-domain and spectral parameters of HRV. Combined administration of w-3 PUFAs and simvastatin promoted to the most statistically significant positive changes of lipid profile, endothelial function, ТХВ<sub>2</sub>,TXB<sub>2</sub>/6-ketoPGF<sub>1</sub><sub>a</sub> levels, time-domain and spectral parameters of HRV. <strong><em>Conclusions.</em></strong><strong> </strong>Obtained results demonstrated that effects of combined simvastatin and omega-3 PUFAs prescription are not connected with diabetes mellitus compensation state and are the results of an direct influence of this pharmacological agents on investigated parameters, that justify the appropriateness of their prescription to patients with T2DM and functional stage of CAN.</p> ER -